Authors
Oliver Preische, Stephanie A Schultz, Anja Apel, Jens Kuhle, Stephan A Kaeser, Christian Barro, Susanne Gräber, Elke Kuder-Buletta, Christian LaFougere, Christoph Laske, Jonathan Vöglein, Johannes Levin, Colin L Masters, Ralph Martins, Peter R Schofield, Martin N Rossor, Neill R Graff-Radford, Stephen Salloway, Bernardino Ghetti, John M Ringman, James M Noble, Jasmeer Chhatwal, Alison M Goate, Tammie LS Benzinger, John C Morris, Randall J Bateman, Guoqiao Wang, Anne M Fagan, Eric M McDade, Brian A Gordon, Mathias Jucker
Publication date
2019/2
Journal
Nature medicine
Volume
25
Issue
2
Pages
277-283
Publisher
Nature Publishing Group
Description
Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for various cerebral proteopathies. Here we leverage the unique characteristics of the Dominantly Inherited Alzheimer Network and ultrasensitive immunoassay technology to demonstrate that NfL levels in the cerebrospinal fluid (n= 187) and serum (n= 405) are correlated with one another and are elevated at the presymptomatic stages of familial Alzheimer’s disease. Longitudinal, within-person analysis of serum NfL dynamics (n= 196) confirmed this elevation and further revealed that the rate of change of serum NfL could discriminate mutation carriers from non-mutation carriers almost a decade earlier than cross-sectional absolute NfL levels (that is, 16.2 versus 6.8 years before the estimated symptom onset). Serum NfL rate of change peaked in participants converting from the presymptomatic to the symptomatic stage and was …
Scholar articles
O Preische, SA Schultz, A Apel, J Kuhle, SA Kaeser… - Nature medicine, 2019